Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
about
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II studyDonor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survivalMixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.Mixed chimerism in SCT: conflict or peaceful coexistence?Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease.New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies.Monitoring of hematopoietic chimerism by real-time quantitative PCR of micro insertions/deletions in samples with low DNA quantities.Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.Chimerism analysis in clinical practice and its relevance for the detection of graft rejection and malignant relapse in pediatric hematopoietic stem cell transplant patients.Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse.Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT.Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation?Quantitative real-time ARMS-qPCR for mitochondrial DNA enables accurate detection of microchimerism in renal transplant recipients
P2860
Q35193763-7BC9E104-D166-407D-9400-CD7CC962E7DEQ35769347-25F79D3D-5F86-4C8F-BD57-E3AC502F8C13Q36157233-88A37ABA-64D3-4301-8702-D725AD2FC680Q36310347-9A6F4992-BE89-41BA-86A8-336B6D18546FQ37228383-4738D748-839A-41A3-8BAB-FEF523E6E2DFQ37337095-E6843FBB-57B8-4862-AB7B-47471C9E4226Q37344050-15672A31-BCD4-4BE4-A566-BF6F28CB7740Q39764454-4B2D7027-89B5-4421-BE3A-C136543B8AAEQ39813829-C39A8D53-AED4-4466-9E3F-785DD803D028Q39835508-70815479-F4BC-4289-AA4D-914A87919F51Q40210739-9F1104FE-9AE1-44C4-843D-C2EE4B28681CQ40625577-31459394-02DF-4E7B-8B4E-F1B29B4F7A9FQ45862572-B3F49CDA-1BC4-484B-AEEE-DAC112121A1EQ46194526-2FE0BFAC-2E9D-40D2-9BCD-B802B936DB16Q46668662-99CE7594-5B7B-412F-9DBE-34B164B1020DQ47124626-87B9FE95-EA83-42C0-86A5-61FC253A8AFCQ47144269-574116DD-2427-4873-83BB-5928E39E519FQ47236287-B58303C5-ECA5-441F-BB38-053AC2E5076DQ50654390-EDD9E394-CA59-4236-9F86-71BD9E1854E9Q50790158-38D0ABB4-0931-4317-9904-878BF6D52378Q52962918-2943554D-1928-499B-A080-6BF78979983CQ54941520-DE64A77D-D4CC-4EA8-9B44-F8316B6F3777Q57712641-DF204DF3-D912-4224-AA05-9936B8DE8129
P2860
Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@en
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@nl
type
label
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@en
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@nl
prefLabel
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@en
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@nl
P2093
P356
P1476
Chimerism analysis within 6 mo ...... pse in acute myeloid leukemia.
@en
P2093
Tilanus MG
Verdonck LF
de Vries L
de Weger RA
P2888
P304
P356
10.1038/SJ.BMT.1705582
P407
P577
2007-01-29T00:00:00Z